Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Asset disposition
Wright Medical Group N.V. (WMGI) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/16/2020 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "Amendment to Articles of Association of Wright Medical Group N.V",
"Memorandum of Association of Stryker Unite, Ltd",
"Bye-Laws of Stryker Unite, Ltd",
"Supplemental Indenture, among Wright Medical Group N.V., Wright Luxembourg S.A., Wright Medical Ltd. and The Bank of New York Mellon Trust Company, N.A",
"Supplemental Indenture, among Wright Medical Group, Inc., Wright Medical Group N.V., Wright Luxembourg S.A., Wright Medical Ltd. and The Bank of New York Mellon Trust Company, N.A"
04/27/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/27/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "AMENDMENT OF THE ARTICLES OF ASSOCIATION"
11/04/2019 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Purchase Agreement, among Wright Medical Group N.V., Stryker Corporation and Stryker B.V",
"Wright Medical Group N.V. Announces Definitive Agreement to be Acquired by Stryker"
08/07/2019 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2019 Second Quarter Financial Results Second Quarter 2019 Net Sales, Including Cartiva ® , of $230 Million, Representing As-Reported Growth of 12%, Constant Currency Growth of 13% and Organic Constant Currency Growth of 9% Second Quarter 2019 Net Loss From Continuing Operations of $19 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $35 Million, Representing Non-GAAP Adjusted EBITDA Margin of 15%, an Approximate 290 Basis Point Expansion Over Prior Year Quarter Company Updates 2019 Annual Guidance Reiterates Long-Term Financial Targets of Double-Digit Constant Currency Net Sales Growth, Gross Margins in High 70s% Range and Non-GAAP Adjusted EBITDA Margin of Mid-20% Range Exiting 2021"
06/28/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2019 First Quarter Financial Results First Quarter 2019 Net Sales, Including Cartiva ® , of $230 Million, Representing As-Reported Growth of 16%, Constant Currency Growth of 18% and Organic Constant Currency Growth of 13% First Quarter 2019 Record Gross Margins of 80% First Quarter 2019 Net Loss From Continuing Operations of $30 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $37 Million, Representing Non-GAAP Adjusted EBITDA Margin of 16%, an Approximate 300 Basis Point Expansion Over Prior Year Quarter Company Reiterates 2019 Annual Guidance"
02/26/2019 8-K Quarterly results
02/08/2019 8-K Quarterly results
02/05/2019 8-K Quarterly results
01/31/2019 8-K Quarterly results
01/07/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Wright Medical Group N.V. Announces Preliminary Fourth Quarter and Full-Year 2018 Net Sales Fourth Quarter 2018 Net Sales, Including Cartiva, of Approximately $238 Million Full-Year 2018 Net Sales, Including Cartiva, of Approximately $836 Million, Exceeds Company’s Previously Provided 2018 Guidance Range Cartiva Revenue of Approximately $9.5 Million From October 10, 2018 Closing Date Company Reaffirms Previously Provided FY 2018 Adjusted EBITDA Guidance Company Provides New Long-Term Financial Targets to Deliver Best in Class Combination of Size, Growth and Adjusted EBITDA Margin Company to Present Today at J.P. Morgan Healthcare Conference at 1:30 p.m. Pacific Time"
12/14/2018 8-K/A Financial Statements and Exhibits
Docs: "FORM 8-K/A",
"Consent of Bennett Thrasher LLP, Independent Auditors",
"Unaudited interim financial statements of Cartiva, Inc. as of September 30, 2018 and for the nine months ended September 30, 2018 and 2017",
"Audited financial statements of Cartiva, Inc. as of and for the year ended December 31, 2017",
"Unaudited pro forma condensed combined financial statements as of and for the nine months ended September 30, 2018 and the year ended December 31, 2017"
10/10/2018 8-K Quarterly results
08/29/2018 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : August 29, 2018 WRIGHT MEDICAL GROUP N.V. The Netherlands 1-35065 98-0509600 Prins Bernhardplein 200 1097 JB Amsterdam The Netherlands None 20 521 4777 Registrant's telephone number, including area code Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exc...",
"Underwriting Agreement, between the Company and J.P. Morgan Securities LLC",
"Opinion of Stibbe N.V",
"Offering of $440 Million Ordinary Shares",
"Wright Medical Group N.V. Announces Pricing of Public Offering of Ordinary Shares AMSTERDAM, The Netherlands - August 27, 2018 -"
08/27/2018 8-K Investor presentation
Docs: "Agreement and Plan of Merger by and among Wright Medical Group, Inc., Braves WMS, Inc., Wright Medical Group N.V., Cartiva, Inc. and Fortis Advisors LLC, as representative †",
"Wright Medical Group N.V. Enters Into Definitive Agreement to Acquire Cartiva, Inc.",
"Investor Presentation issued by Wright Medical Group N.V."
08/08/2018 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2018 Second Quarter Financial Results Second Quarter 2018 Net Sales of $205 Million Second Quarter 2018 Net Loss From Continuing Operations of $91 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $26 Million U.S. Upper Extremities Business Increased 22%, Led by Sales Growth of SIMPLICITI™ Shoulder System U.S. Lower Extremities Business Growth Rate Accelerates to 9%; AUGMENT ® Injectable Approved in U.S. Company Increases 2018 Annual Guidance"
07/03/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Indenture, among Wright Medical Group, Inc., Wright Medical Group N.V. and The Bank of New York Mellon Trust Company, N.A. (including the form of the 1.625% cash convertible senior note due 2023)"
07/02/2018 8-K Submission of Matters to a Vote of Security Holders
06/21/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Exchange/Subscription Agreement, among Wright Medical Group N.V., Wright Medical Group, Inc. and Each Investor Party Thereto",
"Form of Subscription Agreement, among Wright Medical Group N.V., Wright Medical Group, Inc. and Each Investor Party Thereto",
"Wright Medical Group N.V. Announces Private Placement of $675 Million of 1.625% Cash Convertible Senior Notes Due 2023"
05/09/2018 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2018 First Quarter Financial Results First Quarter 2018 Net Sales of $199 Million First Quarter 2018 Net Loss From Continuing Operations of $20 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $27 Million U.S. Upper Extremities Business Increased 21%, Led by Ongoing Launch of PERFORM™ Reversed Glenoid U.S. Lower Extremities Business Growth Rate Accelerates to 2.5% Resolution of U.K. Insurance Dispute Results in $30.75 Million Recovery Company Reaffirms Previously Provided 2018 Annual Guidance"
04/04/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "THIRD AMENDMENT TO THE THIRD SETTLEMENT AGREEMENT, dated October 3, 2017, between Wright Medical Technology, Inc. and Plaintiffs’ Co-Lead Counsel appointed by the Hon. William S. Duffey in MDL No. 2329 and Plaintiffs’ Co-Lead Counsel appointed by the Hon. Jane Johnson in JCCP No. 4710 , is made pursuant to Section 13.10 of the Third Settlement Agreement dated October 3, 2017 . The Third Settlement Agreement, as previously amended by the Second Amendment to the Third Settlement Agreement, shall be further amended as follows :"
02/27/2018 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2017 Fourth Quarter and Full-Year Financial Results and Provides 2018 Annual Guidance Fourth Quarter 2017 Net Sales of $218 Million; Full-Year 2017 Net Sales of $745 Million Fourth Quarter 2017 Net Income From Continuing Operations of $27 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $38 Million Full-Year 2017 Net Loss from Continuing Operations of Negative $65 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of Positive $88 Million U.S. Upper Extremities Business Increased 29%, Led by Ongoing Launch of PERFORM™ Reversed Glenoid Company Provides Full-Year 2018 Net Sales Guidance of $800 Million to $812 Million Company Provides Full-Year 2018 Non-GAAP Adjusted EBITDA Guidance of $104 Million to $111 Million"
01/08/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Wright Medical Group N.V. Announces Preliminary Fourth Quarter and Full-Year 2017 Net Sales Fourth Quarter 2017 Net Sales of Approximately $218 Million Full-Year 2017 Net Sales of Approximately $745 Million At High-End Of Company’s Previously Provided 2017 Guidance Range Company to Present Today at J.P. Morgan Healthcare Conference at 7:30 a.m. Pacific Time"
01/05/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "PLAINTIFFS’ MDL AND JCCP CO-LEAD COUNSEL /s/ Michael L. McGlamry /s/ Raymond P. Boucher Michael L. McGlamry Raymond P. Boucher Pope, McGlamry, Kilpatrick, Morrison & Norwood, P.C. Boucher LLP Dated: December 27, 2017 Dated: December 27, 2017 WRIGHT MEDICAL TECHNOLOGY, INC. /s/ James Lightman James Lightman Sr. Vice President and General Counsel Wright Medical Technology, Inc. Dated: December 29, 2017"
12/14/2017 8-K Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Wright Medical Group N.V. Announces Acquisition of IMASCAP SAS"
11/01/2017 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2017 Third Quarter Financial Results and Updated 2017 Annual Guidance Third Quarter 2017 Net Sales of $170.5 Million Third Quarter 2017 Net Loss From Continuing Operations of $34 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of Positive $12 Million U.S. Upper Extremities Business Increased 19%, Led by Ongoing Launch of PERFORM™ Reversed Glenoid Company Updates Previously Provided Full-Year 2017 Net Sales Guidance to $740 Million to $745 Million Company Increases Full-Year 2017 Non-GAAP Adjusted EBITDA Guidance to $84 Million to $88 Million"
10/04/2017 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : October 3, 2017 WRIGHT MEDICAL GROUP N.V. The Netherlands 1-35065 98-0509600 Prins Bernhardplein 200 1097 JB Amsterdam The Netherlands None 20 521-4777 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communication...",
"Second Settlement Agreement between Wright Medical Technology, Inc. and the Counsel Listed on the Signature Pages Thereto (filed herewith)",
"Tranche 1: $7.9 million to settle 49 additional claims that would have been eligible to participate in the MSA but for the claim limit contained therein, which amount will be funded as such claims are settled;"
08/02/2017 8-K Quarterly results
06/27/2017 8-K Form 8-K - Current report
05/03/2017 8-K Form 8-K - Current report
04/25/2017 8-K Form 8-K - Current report
02/21/2017 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2016 Fourth Quarter and Full-Year Financial Results and Provides 2017 Guidance Full-Year 2016 Net Sales of $690 Million As Reported Exceeds High-End Of Company’s Previously Provided 2016 Guidance Range Fourth Quarter 2016 Net Sales From Continuing Operations of $193 Million As Reported Fourth Quarter 2016 Net Loss From Continuing Operations of $30 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of Positive $23 Million Company Provides Full-Year 2017 Net Sales Guidance of $755 Million to $765 Million"
12/29/2016 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy